CD8A and vitiligo: Treatment with anti-CD122 antibody, a subunit of the IL-15 receptor on human and mouse TRM cells, has been shown to decrease IFN-γ production and to deplete autoreactive CD8+ TRM cells in mice with established vitiligo (Richmond et al., 2018).